Anti-Xa Monitoring: Inter-assay Variability

Thromb Haemost 2000; 84(06): 1122-1123
DOI: 10.1055/s-0037-1614183

Letters to the Editor

Schattauer GmbH

F. Depasse

¹LCL, Ivry-sur-Seine, France

,

M. Gilbert

²Serbio-Diagnostica Stago, Gennevil liers, France

,

V. Goret

²Serbio-Diagnostica Stago, Gennevil liers, France

,

N. Rolland

²Serbio-Diagnostica Stago, Gennevil liers, France

,

M. M. Samama

References
1 Kitchen S, Iampietro R, Wolley AM, Preston FE. Anti-Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82: 1289-93.
2 Sié P, Aillaud MF, De Prost D, Droullé C, Forestier F, Guedj P, Juhan IVague, Polack B, Potron G, Roncato M, Roussi J, Sampol J, Aiach M. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard. Thromb Haemost 1987; 58: 879-83.
3 Abildgaard U, Norrheim L, Larsen AE, Nesvold A, Sandset PM, Ødegaard OR. Monitoring therapy with LM W heparin: a comparison of three chromo genic substrate assays and the Heptest clotting assay. Haemostasis 1990; 20: 193-203.
4 Houbouyan L, Boutiere B, Contant G, Dautzenberg MD, Fievet P, Potron G, Vassault A, Gourmelin Y. Validation protocol of analytical hemostasis systems: measurement of anti-Xa activity of low-molecular-weight heparins. Clin Chem 1996; 42: 1223-30.